<DOC>
	<DOCNO>NCT01576796</DOCNO>
	<brief_summary>This study ass efficacy safety radiotherapy dose complement ( boost ) treatment hypoxic lesion , measure F-miso PET/CT , patient stage III NSCLC amenable surgery candidate chemoradiotherapy . Preliminary study head neck cancer demonstrate feasibility support medical benefit novel approach . The aim study assess efficacy safety radiotherapy dose complement ( boost ) difficult medical condition limit treatment option available .</brief_summary>
	<brief_title>Radiotherapy Dose Complement Treatment Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer</brief_title>
	<detailed_description>Background This phase II study ass efficacy safety radiotherapy dose complement ( boost ) treatment hypoxic lesion , measure F-miso PET/CT , patient stage III NSCLC amenable surgery candidate chemoradiotherapy . There strong theoretical rationale support radiotherapy dose increase patient hypoxic pulmonary tumour . F-miso PET enable vivo identification localisation hypoxic tumoral area , constitute target increase total dose radiation therapy . Preliminary study head neck cancer demonstrate feasibility support medical benefit novel approach . To date , study investigate non-small-cell lung cancer patient perform . Given methodological constraint , propose Gehan plan optimize number subject enrol budget . The project team work image radiotherapy target NSCLC many year within research group identify French National Cancer Institute ( INCa ) 2005 , part axis 3 Northwest Canceropole ( Prof. Gregoire - Prof. Lartigau - Prof. Vera ) 2 . This project present EORTC meeting `` Imaging radiotherapy '' ( organise Dr. Nestlé ) May 28th 2010 . It approve President ESTRO ( Prof. Gregoire ) member SFMN ( French Society Nuclear Medicine ) SFRO ( French Society Radiation Oncology ) `` Imaging Hypoxia '' Meeting September 8th , 2010 . The aim study assess efficacy safety radiotherapy dose complement ( boost ) difficult medical condition limit treatment option available . Objective ( ) clinical study Main objective : evaluate rate local control dose complement hypoxic lesion [ maximum dose without fraction total lung volume receive 20 Gy exceed 30 % lung ( V20 ) ] , determine F-miso PET/CT . Secondary objective : - 3 month 1 year toxicity - Percentage patient RT dose could increase - Simultaneous variation glucose metabolism hypoxia radiotherapy - Predictive value 1-year survival probability variation glucose metabolism hypoxia radiotherapy Main inclusion criterion - Patients stage III non-small-cell lung cancer candidate curative radio-chemotherapy - The final inclusion grant completion dosimetric study confirm dose objective ( minimum dose 60 Gy 99 % target volume ) constraint organs risk achieve . Main assessment criterion - Percentage local control evaluate CT ( RECIST criterion ) FDG PET/CT 3 month Assessment criterion hypoxia Visual analysis : centralize via SFMN net 3 blind reader within 8 day ( Richin , JCO 2006 ) . Definition hypoxia decision boost dose . Quantitative analysis : hypoxic fraction determine retrospectively ( secondary endpoint ancillary study ) . The Gross Target Volume ( GTV ) delineate FDG PET/CT image use adaptive method ( Vauclin , PMB 2009 ) . The contour GTV copy onto F-miso PET image registration . Voxels signal noise ratio great 1.2 consider hypoxic volume . Experimental plan Assumption : increase local control rate 3 month 17 % 40 % . A two-staged Gehan plan implement . The assumption therapeutic efficacy π = 0.4 - In first stage , 6 patient receive radiotherapy dose boost hypoxic lesion . If local control observe 6 patient , trial stop ( power 0.95 ) . In second stage , number patient include determined accord number local control stage 1 , desire precision set ε = 0.10 ( n=19 maximum ) . Number subject require 60 patient significant uptake FDG-PET image neo-adjuvant chemotherapy ( 75 pre-inclusion ) include . Only half 60 patient ( 30 ) expect definitely eligible F-miso PET identify hypoxic area . Out 30 eligible patient , assume 5 evaluable , total 25 evaluable patient assessable .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<criteria>Patients stage III nonsmallcell lung cancer candidate curative radiochemotherapy The final inclusion grant completion dosimetric study confirm dose objective ( minimum dose 60 Gy 99 % target volume ) constraint organs risk achieve . Other cancer evaluable tumor target Absence binding FDGPET test primary chemotherapy Patients radiotherapy curative intent indicate History neoplastic disease le 5 year progressive Patient already include another clinical trial Pregnant , likely breastfeed performance index OMS ≥2 Indicating renal insufficiency Cisplatin treatment Protected adult Unable submit medical study reason geographical , social physical Patients poorly control diabetes blood sugar ≥10 mmol/L hypersensitivity FDG excipients radiopharmaceutical hypersensitivity Fmiso excipients radiopharmaceutical Patients unable understand study ( language ... ) Patients affiliate `` sécurité social ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Fmiso</keyword>
	<keyword>FDG PETSCAN</keyword>
	<keyword>FMISO PETSCAN</keyword>
	<keyword>complement dose</keyword>
	<keyword>lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>hypoxic lesion</keyword>
</DOC>